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Summary 
This paper describes the influence of neu-
roleptic therapy on facial action in drug-naive schizophrenics. 
In a comparative study of medicated and unmedicated schizo-
phrenic patients, the coordinates of 12 small light-reflecting 
points, attached to subjects' faces, were computer-recorded 
and analyzed automatically during a semistandardized clinical 
interview. In addition, facial activity in videotaped interviews 
was coded using the Facial Action Coding System (FACS). 
Each sample group comprised of eight patients with the DSM-
III-R diagnostic criteria "schizophrenia" or "schizophreniform 
disorder". Subjects were studied on two occasions, one shortly 
after admission to the hospital, the other three weeks later. 
Group I was unmedicated during the first session, whereas 
group2 was medicated throughout the study. Three weeks 
after the start of medication, at the second interview, both 
recording methods showed a reduction in facial activity and 
facial expression across all subjects in group 1. The facial 
action of patients in group2, however, remained unchanged. 
Introduction 
Unusual facial expresslvlty in schizophrenic 
patients is a well-established phenomenon. Facial expressions 
of schizophrenics are frequently described as bizarre, emotion-
less, rejecting, and uncoordinated in the literature because they 
display a lack of holistic configurations during the general pace 
of expression (Esquirol, 1838; Morison, 1853). These features 
had been mentioned long before the discovery of neuroleptics 
(Bleuler, 1911 , Kraepelin, 1883) and have been repeatedly em-
phasized in the past by psychiatrists (Marsden et aI. , 1975; 
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Der Einflu6 von Neuroleptika auf die 
Mimik schizophrener Patienten 
Ziel der vorliegenden Arbeit war die Untersu-
chung des Einflusses von Neuroleptika auf die Mimik von 
unmedizierten schizophrenen Patienten. Wiihrend eines halb-
standardisierten klinischen Interviews worde die Beweglich-
keit von zwolf kleinen, licht-reflektierenden Punkten, die in 
das Gesicht von medizierten und unmedizierten schizophre-
nen Patienten geklebt worden, automatisch im Zeitverlauf ge-
messen. Erganzend wurde der mirnische Ausdruck mit dem 
Facial Action Coding System (FACS) kodiert, wofiir die Pati-
enten gleichzeitig mit Video aufgenommen worden. Jede der 
beiden Gruppen bestand aus acht Patienten mit den DSM-III-
R-Diagnosen "Schizophrenie" oder "Schizophrenieforme Sto-
rung". Die Patienten worden einmal direkt nach der stationa-
ren Aufnahme und ein zweites Mal nach drei Wochen unter-
sucht. Die Patienten der ersten Gruppe waren zum ersten Zeit-
punkt nicht mit Neuroleptika mediziert, wiihrend die der zwei-
ten Gruppe schon zu diesem Zeitpunkt entsprechende Medi-
kamente einnahmen. Es konnte eine Reduktion der mimischen 
Beweglichkeit des gesamten Gesichtes im Sinne einer neuro-
leptisch bedingten Hypornimie der primiir Neuroleptika-unbe-
handelten Patienten bei der zweiten Untersuchung beobachtet 
werden. Die andere Gruppe Schizophrener, die zu beiden Zeit-
punkten mit Neuroleptika behandelt waren, zeigte keine Ver-
iinderung in ihrer mimischen Beweglichkeit. 
Owens et aI. , 1982; Rogers and Hymas, 1988). Moreover, the 
facial expressivity of schizophrenic patients seems to elicit a 
"praecox-feeling" in the diagnostician. To date, researchers 
have been unable to operationalize this diagnostic inclination in 
terms of facial expressivity due to the unavailability of appro-
priate instruments for assessment. 
Only within the last few years have experimen-
tal studies of the facial expressions of schizophrenic patients 
employing valid designs and data analyses (e. g., Krause et aI. , 
1989; Martin et aI. , 1990; Pitman et aI., 1987; Schneider et aI., 
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1992; Steimer-Krause et aI., 1990). In one of our previous stu-
dies (Schneider et aI., 1990) we were able to specifY some 
characteristics of facial expressivity across time in schizo-
phrenic patients with a computer-based analysis of facial action 
(at that time the analysis was limited to four facial points). The 
sum of these features was described as disintegrative facial 
action (cf. Heimann and Spoerri, 1957): a reduction of facial 
action in the upper facial region during a social interaction 
condition, facial action indifference in response to disparate 
emotional and situational stimuli, as well as the inability of the 
observers to rate the intensity of expressed facial action as 
objectively as the computer analysis on an intensity rating scale. 
Furthermore, it remained unclear to what extent these experi-
mentally induced effects in schizophrenics are of nosological 
significance, since a reduction of facial action in the upper 
region of the face was also found in depressives. An unsolved 
question is whether this effect may possibly be an indicator of 
severity of illness. Another plausible assumption may be that 
the conspicuous facial actions found in schizophrenics are 
simply extrapyramidal side-effects of neuroleptic medication 
expressed as reduced facial activity. Moreover, it is known that 
neuroleptics affect those cortical and subcortical structures 
which regulate upper facial activity (Rinn, 1984) . . 
The objective of this study was to describe 
changes in facial movements in schizophrenics over the course 
of therapy, in order to analyze the effects of neuroleptics (by 
quantitatively assessing a reduction of facial actions caused by 
neuroleptics) and the effects of improved clinical status on the 
patients' facial actions. We used two different types of analyses. 
The first analysis was quantitative in that facial activity was 
assessed by a rater-independent automatic analysis, while the 
other assessment was a qualitative behavior analysis which 
involved the systematic observation of facial behavior by 
means of the Facial Action Coding System (FACS) (Ekman 
and Friesen, 1978) and itS coding in terms of individual action 
units. 
Method 
Patients 
Two groups of eight schizophrenic or schizo-
phreniform patients participated in this study (DSM-IlI-R-Cri-
teria; diagnosed by a German version of the Structural Clinical 
Interview according to DSM-III-R [SCID)) (Wittchen et aI. , 
1987). Table 1 contains demographic and clinical data of the two 
groups. Table 2 lists the medications and their side-effects. 
In contrast to patients in group 2, patients in 
group I were unmedicated at the first session. Six of these 
patients had never been on any neuroleptics before, while the 
other two had stopped using neuroleptics 13 / 50 weeks prior to 
study onset. 
Patients in group 1 were given neuroleptics im-
mediately following the first session (T I)' Neuroleptics and 
dosage were based on the clinical state of the patients. Group 2 
simply continued taking the medication. The second recording 
(T 2) was done approximately 22 days later. 
The following expert rating scales were used 
after each of the two sessions: Global Assessment Scale (GAS) 
(Endicott et aI., 1976), Brief Psychiatric Rating Scale (BPRS) 
F Schneider et al. 
Tab. 1 Demographic und clinical data. The improvements in clinical 
state from T 1 to T 2 (3 weeks) were significant on all scales in both 
groups, see text. 
Variable 
Gender 
Age 
Diagnosis 
(DSM III-R) 
Group 1 
(unmedicated) 
6m/2f 
26.1 y./SD= 5.2 
295.1 2 
295.3 1 
295.4 1 
295.9 4 
First 
occurrence 
Duration 
of current 
episode 
GAS 
Tl 
T2 
BPRS 
Tl 
T2 
SANS (SS) 
Tl 
T2 
3 yes / 5 no 
24.0 w/SD = 34.4 
M=29.4/SD= 9.0 
M=41.3/S0= 12.8 
M= 58.8/SD= 14.8 
M=44.1/SD= 10.5 
M= 16.6/ SD= 4.7 
M= 12.6/SD= 3.7 
Group 2 
(medicated) 
5m/3f 
26.1 y. /SD = 11.5 
o 
1 
2 
5 
3 yes/5 no 
8.6 w/SD = 8.0 
t-test 
tip 
(df=14) 
0.62 /ns 
-1.22/ns 
M=36.0/ SD= 8.0 -1.53/ns 
M=48.5/S0= 7.6 1.34/ns 
M=60.1/S0= 13.6 0.19/ns 
M = 36.5/SD = 8.3 -1.61/ns 
M= 16.0/S0= 3.2 -0.31/ns 
M= 11.3/S0= 2.6 0.87/ns 
Tab. 2 Medication and side-effects (n : number of patients) 
Variable Group 1 Group 2 t-test 
(unmedicated) (medicated) tiP (df= 16) 
Neuroleptics 
Tl (n) 0 8 
T2 (n) 8 8 
Antidepressives 
Tl (n) 0 
T2 (n) 0 
Benzodiazepine 
Tl (n) 3 6 
T2 (n) 6 4 
Biperiden 
Tl (n) 0 5 
T2 (n) 6 5 
CPZ 
Tl (M/ SD) 0 1165/660 
T2 (M/SD) 519/227 877 /464 1.96/n. s. 
RSES 
Tl (M/SD) 0 2.5/1.0 
T2 (M/SD) 3.8/2.6 2.8/1.7 0.79/n. s. 
(Overall and Gorham, 1962), and Scale for the Assessment of 
Negative Symptoms (SANS) (Andreasen, 1981). 
Dosage calculations of chlorpromazine units 
were based on the procedure proposed by Davis (1974), while 
extrapyramidal side-effects were assessed using the Rating 
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Scale for Extrapyramidal Symptoms (RSES: Parkinsonian syn-
drome, akathisia, dystonia) (DiMascio et a\. , 1976). 
Significant improvements in clinical state 
from TI to T2 were registered on all scales in both groups (cf 
Table 1 for mean values and standard deviations; t-tests for de-
pendent variables (df = 7): 
a) group 1: GAS: t=-3.80; p=.007; BPRS: t=3.73; p=.OO7; 
SANS-SS: t=2.41; p=.047 
b) group 2: GAS: t=- 3.38; p= .012; BPRS: t=6.30; p= .OOO; 
SANS-SS: t=4.61; p= .002. 
Experimental procedure 
The experimenter conducted a semistandard-
ized interview. The patient was asked questions about his / her 
general well-being, about the illness, and about how the in-
dividual was coping with his present situation. The interview 
lasted about ten minutes. After the initial questions, a period of 
2.5 min was allowed for behavioral analysis. This was to ensure 
that the patients had already adjusted to the experimental set-
ting. We limited the facial action assessment to 2.5 min because 
the analysis is very time-consuming and the time period is 
nevertheless a clinically relevant time segment. 
Automatic facial analysis 
With small round foil (diameter: 2.0 rum) at-
tached to different regions of the patient's face, we analyzed the 
range of facial action with the help of a computer program 
developed at our institute (Himer et aI., 1991). The specially 
constructed scanning unit has a resolution of 1024 x 2048 pixels 
(horizontal x vertical), and scans 10 pictures per second. The 
yoked computer eliminates head movements and computes the 
X and Y coordinates for each facial action point with the help 
of four points of reference. The distance a point moves within 
the specified time is recorded and standardized (averaged 
across one second). The effect of the digital white noise on the 
computed point activity is 1.74 rum / sec. 
In this study we assessed the mobility of 12 
facial action points: Four facial action point foils were placed 1 
cm above the inner/outer right and left eyebrow respectively, 
two 3 cm below the outer edges of the lower eyelid, two about 
I cm away from the nostrils, two close to the lip comers as well 
as about I cm above and below the midline of the mouth (Fig. 
1). Since we took pictures of all of the patients with the attached 
facial action points at T I, we were able to replicate the precise 
position of each point at T 2. 
Facial Action Coding System 
With the Facial Action Coding System (FACS) 
(Ekman and Friesen, 1978) facial expressions can be measured 
in a systematic manner. FACS is based on the functional ana-
tomical structure of the facial musculature. It comprises 44 
individual action units (AU), each representing a specific 
muscular facial action. At a speed of 25 video-frames / sec a 
temporal resolution of 40 msec is possible. The coding of facial 
expressions with FACS is done in two separate steps, first 
coding the upper face and then the lower face. The coding was 
done independently by trained observers after passing the final 
.6 3'010 
Fig. 1 Position of 
facial action points. 
test lor reliability. These observers also coded in real-time on-
off patterns of vocalization during the interview. 
Statistical analysis 
The hypothesis of a reduction of facial action 
due to neuroleptics was analyzed with the help of unidirectional 
t-tests. Furthermore, we analyzed the data with global ANOVAs 
and bidirectional t-tests. Intragroup -comparisons between T I 
and T2 were performed using repeated-measure designs. 
Results 
Global parameter of facial activity 
Automatic analysis 
When averaged across 12 facial action points, 
a significant reduction of facial actions could be observed in 
group 1 (unmedicated at T\) when TI 'and T2 were compared 
(TI: M=2.52 rum/ sec, SD= 1.75; T2: M= 1.45, SD=0.37; 
t(7)=2.06; p = .037; one-tailed). The facial actions in group 2 
did not change significantly. The results were as follows: 
1.70 rum / sec (SD=0.78) at TI and 1.97 (SD= 1.02) at T2 
(t(7) =-0.99). 
The significant effects of a 2 x 2 x 12-ANOVA 
with the factors "Group" (1,2), "Time" (TI,T2) and "Facial 
Action Point Position" (1-12) using repeated measures con-
firmed these results: GroupxTime (F(1,14)=5.21; p=0.039), 
and GroupxTimexFacial Action Point Position (F(11,154)= 
2.18; P = .018). Additionally, there was a significant main effect 
on Facial Action Point Position (F(1l,154)=24.39; p=.OOO), 
which was why we further analyzed the data separately for the 
upper and lower face . 
FACS 
A significant reduction of facial actions in 
group 1 could be observed during the course of the first three 
weeks (TI to T2)' Also noticeable was a clear reduction in the 
236 Pharmacopsychiat. 25 (1992) F Schneider et al. 
• b c d Fig. 2 Automatic ana-17 Inner eyebrows ~7 lower face 17 Inner eyebrows 17 lower face lysis: a comparison of 
6 6 6 6 means (mm/sec) of 
5 5 5 5 
both inner eyerbrow 
points with the means 
.. .. 
.. .. of six other facial 
3 3 ·3 3 
action points of the 
lower face for 8 un-
2 2 2 28 2 medicated patients ~ (group 1; a, b) and 
, ---------------
8 medicated patients 
0 0 0 0 , (group 2; C, d). The 
T1 T2 T1 T2 T1 T2 T1 T2 total number of AUs 
8 g h (FACS) in the lower 
5'50 Inner eyebrows ~5O lower face 5 50 Inner eyebrows 550 lower face region of the upper So So So face and the lower 
-40 
-40 -40 -40 face of unmedicated 
30 30 30 30 (group 1; e, f) and me-
20 20 20 20 
dicated schizophrenic 
patients (group 2; g, h) 
10 10 10 10 at T 1 and T 2 is also ~ ~t 0 .. 1 0 shown . 0 r 0 , i , 
T1 T2 T1 T2 
Tab. 3 Means (above) und standard deviations (below) of the activity 
(in mm/s) of the individual facial action points across group 1 and 
group 2. 
Position Group 1 Group 2 
(unmedicated) (medicated) 
T1 T2 Tl T2 
1 right cheek 1.99 0.92 1.07 1.67 
1.75 0.40 0.70 1.15 
2 right outer brow 1.57 0.51 0.47 0.68 
2.07 0.58 0.50 0.99 
3 left lip corner 3.12 1.99 2.11 2.92 
1.79 0.84 1.02 1.81 
4 right nostril 1.42 1.15 1.12 1.60 
0.79 0.33 0.56 1.17 
5 right inner brow 0.73 0.83 0.64 0.64 
0.73 0.41 1.10 0.94 
6 upper lip 3.02 1.92 1.93 1.91 
2.75 1.64 1.16 1.91 
7 lower lip 7.44 4.61 5.92 6.50 
5.87 3.76 2.93 3.51 
8 left inner brow 0.91 0.55 0.93 0.74 
1.01 0.64 0.72 0.59 
9 left nostril 1.72 0.92 1.48 1.61 
1.08 0.49 0.66 0.96 
10 left lip corner 4.39 2.27 2.29 3.06 
3.00 0.86 1.18 1.96 
11 left outer brow 1.17 0.52 0.65 0.53 
0.75 0.77 0.87 0.75 
12 left cheek 2.82 1.17 1.72 1.73 
1.80 0.71 0.72 1.05 
T1 T2 T1 T2 
total number of AUs in all patients (TI: M=34.75, SO = 13.0; 
T 2: M = 13.50, SO = 12.5; t (7) = 3.20; p = .008; one-tailed). 
Furthermore, the nonmedicated patients 
showed a significant reduction in AU repertoire, i.e., the varia-
bility of facial expressions at T 2 in comparison to T 1 (T I: M = 
12.13, SO=2.7; T2: M=6.37, SO=4.1; t (7)=2.63; p = .034). 
The average duration of the individual AUs (in sec) did not 
differ significantly at T I or T 2 (T I: M = 1.88, SO = 0.6; T 2: M = 
2.59, SO= 1.1; t (7)=-2.04; p= .080). 
No significant differences could be detected in 
group 2 when comparing these parameters at T I and T 2. 
The group comparison at TI showed that the 
unrnedicated patients (group I ) manifested more facial actions 
than group 2. The total number of AUs was somewhat higher in 
group 1 than in group 2 (group 1: M = 34.75, SO = 13.0; group 
2: M = 19.75 , SO= 12.0; t (14)=2.39; p=.016; one-tailed). 
The difference became even more obvious in the number of 
different AUs displayed, i. e., in the facial action repertoire 
(group 1: M=12.13, SO=2.7; group 2: M=7.88, SO = 4.3; 
t (14)= 2.37; p = .033). No significant differences could be ob-
served in the average duration (in sec) of a single AU (group 1: 
M= 1.88, SO=0.6; group 2: M=2.43, SO= 1.9; t (14)= - 0.69; 
n.s .) 
At T 2, there were no significant differences be-
tween the two groups with regard to these parameters. 
Upper fa ce 
Automatic analysis 
At TI and T2, there was no difference in facial 
activity as measured by the facial action points at the inner 
eyebrows (points 5 and 8) of group 1 (t(7) = 0.44; n. s.). 
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Tab. 4 Means of the most important FACS Action Units for both 
groups at T 1 and h 
Group 1 Group 2 
Number and name of (unmedicated) (medicated) 
the Action Unit Tl T2 Tl T2 
AU1 "inner brow raise" 1.4 0.4 2.0 2.1 
AU2 "outer brow raise" 2.4 0.4 2.1 1.4 
AU4 "brow lower" 0.9 0.4 0.1 0.3 
AU5 "upper lid raise" 0.4 0.0 0.1 0.1 
AU6 "cheek raise" 2.4 0.1 0.8 1.0 
AU7 "lid tighf 1.8 0.3 0.3 0.0 
AU9 "nose wrinkle" 0.0 0.0 0.1 0.1 
AUlO "upper lip raise" 1.0 0.3 0.3 0.1 
AU12 "lip corner pull" 4.6 2.4 1.4 3.8 
AU14 "dimpler" 0.6 1.1 1.5 0.6 
AU15 "lip corner depress" 1.1 0.3 1.3 1.4 
AU16 "lower lip depress" 0.1 0.4 0.0 0.0 
AU17 "chin raise" 3.0 2.5 1.1 0.1 
AU18 "lip pucker" 0.6 0.1 0.0 0.4 
AU20 "lip stretch" 2.1 0.1 0.5 0.9 
AU22 "lip funnel" 0.5 0.0 0.1 0.0 
AU23 "lips tighf 1.3 0.6 1.0 1.0 
AU24 "lip press" 1.8 1.8 1.3 0.8 
AU25 "lips part" 1.6 0.3 0.6 1.1 
AU26 "jaw drop" 2.6 0.5 1.4 2.0 
AU28/32 "lip suck/ bite" 1.3 0.4 1.3 1.6 
AU-combination 1 + 2 1.3 0.4 1.5 1.3 
AU-combination 6 + 12 2.1 0.1 0.8 1.0 
FACS 
Between T 1 and T 2, there was a reduction in the 
total frequency of AUs I and 4 in group 1 (T I: M = to.OO, SD = 
7.1 ; T2: M =2.00, SD = 2.2; t(7) =2.2; p= .015; one-tailed). The 
reduction in facial actions not only involved the concomitant 
upper facial activity when the patient was talking but also other 
AUs which can be regarded as indicator of emotional expres-
sions (cr. Table4). 
Lower face 
Automatic analysis 
A comparison ofTI and T2 for the facial action 
points of the lower face (points 3,4,6,7,9, and lO) showed a 
significant reduction in facial actions in group I at T 2 (t (7) = 
2.01 ; p =.042; one-tailed), and therefore reflect diminished ac-
tivity of the lower face at T 2. 
FACS 
Group 1 demonstrated a significant reduction 
in facial actions (AU9,lO, 12-15, 17,18,20,22- 28,30, and 32) 
in the time between TI and T2 (TJ: M=24.75, SD= 11.2; T2: 
M = 11.50, SD = 11 .8; t (7) = 2.46; P = .022; one-tailed). 
The reduction in individual AUs in the lower 
face is rather striking: the obvious reduction in AUs 12 and 20, 
as well as in AUs 10 and IS, indicate a reduced ability to 
express accompanying emotions. The reduction in AUs 25 and 
26 indicates the concurrent reduction in general facial activity. 
AUs 14, 17, and 24, which belong to a group of AUs that repre-
sent accompanying emotional expressions, did not show any 
reduction at T2. 
Verbal activity 
The fmdings presented are independent of the 
relative amount of vocalization during the interview (length of 
verbal activity in relation to duration of the interview). The 
relative verbal activity in group I was 38.5 % at T 1 (SD = 16.6) 
and 32.3% (SD= 14.2) at T2 (t (7)= 1.84; n.s.), while in 
group 2 it was 36.6. % (SD= 14.1) at Tl and 34.6% (SD = 9.1) 
at T 2(t (7) = 0.34; n. s.). 
Discussion 
The patients in the two groups did not differ as 
to diagnoses, case history, psychopathology, age, or psychiatric 
inpatient treatment at T 1 and T 2. They did differ with regard to 
the onset of medication: group I was unmedicated at T 1 while 
group 2 was medicated. Moreover, six out of eight patients in 
group 1 had never been on any neuroleptics. 
Computer-based facial action analysis allows 
the reduction of global facial activity in a typical clinical inter-
action to be attributed to the influence of neuroleptics (interac-
tion: Group x Time with a three-factorial ANOYA). The vari-
ance in average facial activity in group I was significantly re-
duced at T 2 compared to T 1 (cf. Table 3): Inter-individual varia-
bility in group I was lower at T 2, and can therefore be attributed 
to the effects of neuroleptics. 
Consequently, an objective assessment method 
is now available which can measure neuroleptically induced 
reductions in facial actions automatically. (In this respect, it 
might be of interest that See and coworkers were able to observe 
a reduction in oral activity in rats which had been on neurolep-
tics for a long time, although they used a different procedure 
(Ellison et aI., 1987; Levyet aI., 1987; See et aI., 1988).) 
As expected, no group differences with respect 
to facial actions could be observed at T 2 (about three weeks 
after TI), as both groups were then receiving medication. 
FACS produced almost the same results: it also 
showed a significant reduction in facial actions in group I be-
tween T 1 and T 2. Furthermore, the total number of facial actions 
was significantly reduced and a significant reduction in the 
variability of the facial action repertoire could also be observed. 
When comparing both groups at T I, group I 
differed significantly from group 2 with respect to the reper-
toire of facial actions. This difference in group 2 might have 
been caused by the neuroleptics they were taking, since neu-
roleptics are known to induce a reduction in facial expressivity 
in schizophrenic patients (cf. Schneider et aI. , 1990). 
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Of further interest is the way in which facial 
actions are reduced under neuroleptics; i. e., the reduction in 
intensity of facial actions in group 1 between T I and T 2 was not 
the same for all facial action points. This effect was quite pro-
nounced for the two facial action points attached below the 
inner eyebrow: no significant changes were observed. Both 
methods corroborated this result (cf. Fig.2). 
Both action points attached below the inner 
eyebrow, that means the underlying muscles, namely the corru-
gator muscle, could possibly playa specific role in the regula-
tion of social interactions (cf. Ekman, 1979 and Grammer et aI., 
1988). Consequently, it may well be that reduced facial activity 
is confounded by improvement. This assumption could possibly 
be attributed to the fact that neuroleptics may have an effect on 
specific areas of the brain: the muscles of the upper facial 
region are functionally more closely connected to the formatio 
reticularis, the basal ganglia, and the "emotional" centers of the 
brain, whereas the muscles of the lower facial region are more 
under volitional control of the individual, since they are 
governed by the speech centers (Rinn , 1984). 
When an improvement in well-being occurs, it 
is generally accompanied by an increase in verbal activity and, 
secondly, by more so-called illustrators, which are mostly ex-
pressed within the upper-middle facial region. The activity of 
the two facial action points attached above the inner eyebrow 
did not increase in group I fromTI to T2, but remained rela-
tively constant (in comparison to the other facial action points, 
whose activity decreased significantly) (cf. Fig.2), while psy-
chopathology also improved significantly. The relative stability 
of the facial activity of the two inner facial eyebrow points, 
assessed by automatic analysis, was verified by FACS, although 
the danger of a bottom effect is much more likely with FACS 
than with automatic analysis. On the other hand, possible arti-
facts in the automatic analysis can be detected by validation 
with the FACS scores. 
I f the previously introduced speculation would 
be correct, that the neuroleptically induced reduction in facial 
activity is confounded by an increase in facial activity during 
improvement, two opposing rendencies would exist. It remains 
an open question whether the reduction in facial activity in-
duced by neuroleptics is a result of both motor and emotional 
sedation, which changes again during recovery. 
With FACS, the individual AUs and their com-
binations can be assigned to specific emotions. A noticeable 
reduction in facial activity in group I was mostly expressed by 
AUs indicative of smiling. The most frequently recorded AU 
was AU 12 and the AU-combination 6+ 12. The latter repre-
sents a "real" smile, and also involves the facial regions around 
the eye. This social smile in an interview situation is important 
in communication. The individual informs his partner that he l 
she is in a friendly mood and thus reinforces that verbal activity 
of his partner positively. 
Similarly, the AUs 20, 10 and 15 were signifi-
cantly reduced. AU 20 is a measure off ear. The AUs 10 und 15 
represent the negative emotions disgust and sadness. A reduc-
tion of expressed fear corresponds well with the psychopatho-
logic improvement observed between T I and T 2 during the 
course of therapy. No reduction took place in AU 17, which 
F Schneider et al. 
represents embarrassment, or the AUs 14 and 24 (representing 
anger). The fact that the facial expressions of embarrassment 
and anger did not manifest a reduction, unlike other areas of 
facial activity, which were significantly reduced, is also indica-
tive of improved psychopathologic symptomatology. 
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